[Federal Register Volume 84, Number 175 (Tuesday, September 10, 2019)]
[Notices]
[Pages 47557-47558]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-19534]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 50-608; NRC-2019-0173]


SHINE Medical Technologies LLC

AGENCY: Nuclear Regulatory Commission.

ACTION: Operating license application; receipt and availability.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) staff 
acknowledges receipt of an application submitted by SHINE Medical 
Technologies, LLC (SHINE), dated July 17, 2019, filed

[[Page 47558]]

pursuant to the Atomic Energy Act of 1954, as amended, and the NRC's 
regulations, for an operating license for the SHINE Medical Isotope 
Production Facility.

DATES: This action takes effect on September 10, 2019.

ADDRESSES: Please refer to Docket ID NRC-2019-0173 when contacting the 
NRC about the availability of information for this action. You may 
obtain publicly-available information related to this action by any of 
the following methods:
     Federal Rulemaking Website: Go to https://www.regulations.gov/ and search for Docket ID NRC-2019-0173. Address 
questions about NRC docket IDs in Regulations.gov to Jennifer Borges; 
telephone: 301-287-9127; email: [email protected]. For technical 
questions, contact the individual listed in the FOR FURTHER INFORMATION 
CONTACT section of this document.
     NRC's Agencywide Documents Access and Management System 
(ADAMS): You may obtain publicly-available documents online in the 
ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``Begin Web-based ADAMS 
Search.'' For problems with ADAMS, please contact the NRC's Public 
Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or 
by email to [email protected]. The ADAMS accession number for each 
document referenced (if it is available in ADAMS) is provided the first 
time that it is mentioned in this document.
     NRC's PDR: You may examine and purchase copies of public 
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland 20852.

FOR FURTHER INFORMATION CONTACT: Steven T. Lynch, Office of Nuclear 
Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 
20555-0001, telephone: 301-415-1524; email: [email protected].

SUPPLEMENTARY INFORMATION: By letter dated July 17, 2019 (ADAMS 
Accession No. ML19211C044), SHINE filed with the NRC, pursuant to 
Section 103 of the Atomic Energy Act and part 50, ``Domestic Licensing 
of Production and Utilization Facilities,'' of title 10 of the Code of 
Federal Regulations (10 CFR), an application for an operating license 
for the SHINE Medical Isotope Production Facility to be located in 
Janesville, Wisconsin (ADAMS Package Accession No. ML19211C143).
    SHINE has proposed to construct and operate a facility in 
Janesville, Wisconsin for the production of molybdenum-99 (Mo-99) 
through the irradiation and processing of a uranyl sulfate solution. As 
described in the operating license application, the proposed facility 
would comprise an irradiation facility and radioisotope production 
facility. The irradiation facility would consist of eight subcritical 
operating assemblies (or irradiation units), which would each be 
licensed as a utilization facility, as defined in 10 CFR 50.2, 
``Definitions,'' and supporting structures, systems, and components 
(SSCs) for the irradiation of low enriched uranium. The radioisotope 
production facility would consist of hot cell structures, licensed 
collectively as a production facility, as defined in 10 CFR 50.2, and 
associated SSCs for the processing of irradiated material and 
extraction and purification of Mo-99. The irradiation facility and 
radioisotope production facility are collectively referred to as the 
SHINE Medical Isotope Production Facility. Issuance of the operating 
license would authorize the applicant to operate the SHINE Medical 
Isotope Production Facility for a 30-year period.
    By letters dated March 26 and May 31, 2013 (ADAMS Accession Nos. 
ML13088A192 and ML13172A361, respectively), SHINE (at the time known as 
SHINE Medical Technologies, Inc.) submitted a two-part construction 
permit application, as updated in 2015, for its eight utilization 
facilities and one production facility (ADAMS Package Accession No. 
ML15258A431). The NRC issued Construction Permit No. CPMIF-001 to SHINE 
on February 29, 2016 (ADAMS Package Accession No. ML16041A473).
    The acceptability of the tendered application for docketing and 
other matters, including an opportunity to request a hearing, will be 
the subject of subsequent Federal Register notices.

    Dated at Rockville, Maryland, this 5th day of September, 2019.

    For the Nuclear Regulatory Commission.
Steven T. Lynch,
Project Manager, Research and Test Reactors Licensing Branch, Division 
of Licensing Projects, Office of Nuclear Reactor Regulation.
[FR Doc. 2019-19534 Filed 9-9-19; 8:45 am]
BILLING CODE 7590-01-P